Responses

I am writing to request the following under the Freedom of Information Act, regarding use of and provision for the DASH checklist, aka Domestic Abuse, Stalking and Honour Based Violence

1. Is the DASH RIC used by your organisation as part of services (e.g. domestic abuse provision, victim support)?
2. Is the use of DASH RIC a standard provision or a requirement in contracts with third-party providers of relevant services (e.g. domestic abuse services, sheltered housing)?
3. If the DASH checklist is used by your organisation, which organisation or organisations provide the training that includes DASH training? (e.g. Domestic Abuse Matters training)
4. What is the cost to your organisation of such training? Please break this down by financial year over the last five years, as well as by organisation (if more than one organisation provides the relevant training)

Please provide the following information, Any and all annual data on record to the present day.

1. How many patients have been referred to the trust and presented for the treatment of BRUXISM (Grinding of the teeth)?

2. Please provide geographical date in regards which hospital the patients presented to.

3. Annual cost to the trust and its subsidiaries.

Does the Trust have a staff policy in respect of the wearing/use of fragranced products? Please provide a copy of your staff policy concerning the wearing/use of fragranced products (including use of fragranced laundry products). Where terms such as ‘overwhelming’, ‘overpowering’ or ‘discreet’ are used in respect of fragrance, how are these terms defined and who decides if the level of scent contravenes the guidance: the wearer, the Trust or the patient? How is the policy brought to the attention of staff? Is the policy in respect of the wearing of fragranced products enforced? How is it enforced? What training is given to staff to make them aware that the use of fragranced products can be an accessibility barrier for patients? Please provide details. If any such material is third party copyrighted, please provide a synopsis. Please provide copies of any correspondence, memos or minutes of meetings pertaining to discussion of the use of/ wearing of fragranced products by staff, including use of fragranced laundry products to wash clothing worn at work.

In accordance with the Freedom of Information Act, could you kindly confirm the name of your Trust’s Integration Engine?

I am writing to request information under the Freedom of Information Act 2000.
After reviewing your website and other publicly available information, I have not been able to identify the appropriate contact details for third parties (such as suppliers or service providers) to send formal legal correspondence to your organisation.
Please could you confirm the following:
1. Whether your organisation has one or more specific teams, departments, or named individuals responsible for receiving formal legal correspondence from third parties.
2. The relevant postal address(es), email address(es), and telephone number(s) that such correspondence should be directed to. If responsibility differs by type of issue (e.g. contractual, procurement-related, legal) or by region, please provide the details for each as applicable.
3. If this information is already published, please confirm where it can be found.
This request is made in the public interest to ensure there are clear and transparent routes for formal engagement with public authorities.

I wish to make a freedom of information request and would be grateful if you could provide the following information within 20 working days:

a) The number of staff employed at your Trust’s Sexual Assault Referral Centre (SARC) for the years 2010 – 2024.

b) The number of children aged under 18 years old who have been received support by your Trust’s SARC between the years 2010 – 2024 and, if possible, the number of these who are identified as having been victims of gang-based CSE.

c) The number of victims of CSE who received mental health support from your trust between 2018 and 2024.

d) The number of children identified by your Trust as requiring safeguarding measures as a result of CSE between the years 2010 and 2024.

This should not exceed any cost limits you may have but should you, for whatever reason, decide that it does, the please proceed with parts a – c.

(1) Has your Trust procured any pancreatic enzyme replacement therapy (PERT) products from overseas suppliers between January 2023 and present? Please respond with yes or no. If yes, please answer the following: (a) Which countries were these products sourced from? (b) How many ‘special order’ prescriptions for these products have been dispensed? (c) What percentage of the local demand has been covered by these overseas products?

I would like to please request information relating to the following question –

1. In the last 12 months, how many unique patients in your trust were treated with the following products:

A) Curosurf
B) Peyona

I would like to submit an FOI request for the following data for Gloucestershire Health and Care NHS Foundation Trust:
• The number of patients treated for Dravet syndrome in 2024, ideally separated by month, or quarter
o Patient numbers segmented by age:
 0-3 years old
 4-8 years old
 9-18 years old
 18 years+
• The number of patients treated for Dravet syndrome in 2025, ideally separated by month, or quarter
o Patient numbers segmented by age:
 0-3 years old
 4-8 years old
 9-18 years old
 18 years+
• The number of patients treated for Lennox-Gastaut syndrome in 2024, ideally separated by month, or quarter
o Patient numbers segmented by age:
 0-3 years old
 4-8 years old
 9-18 years old
 18 years+
• The number of patients treated for Lennox-Gastaut syndrome in 2025, ideally separated by month, or quarter
o Patient numbers segmented by age:
 0-3 years old
 4-8 years old
 9-18 years old
 18 years+
• The above data separated by treatment, focusing on the following treatments:
o fenfluramine
o sodium valproate
o stiripentol
o clobazam
o cannabidiol
o levetiracetam
o topiramate
o potassium bromide
o Other treatments
 carbamazepine
 gabapentin
 lacosamide
 lamotrigine
 oxcarbazepine
 phenobarbital
 pregabalin
 tiagabine
 vigabatrin
 rufinamide
• Numbers of patients moving from one specific treatment to another e.g. fenfluramide gains from cannabidiol, sodium valproate losses to cannabidiol
• Alternatively, just the numbers of patients on each treatment for each month/quarter will be able to show how the numbers on each treatment are changing

Under the Freedom of Information Act 2000, I would be grateful if you could provide the following information:
1. Adherence to National Guidelines
Does your Trust currently follow any of the following national guidelines for the treatment and management of Overactive Bladder (OAB)? Please indicate “Yes” or “No” for each of the following:
a) NICE Interventional Procedure Guidance on sacral nerve stimulation for urge incontinence and urgency-frequency (IPG64)
b) NICE Clinical Guideline on Urinary Incontinence in Women (CG171)
c) NICE Clinical Guideline on Lower Urinary Tract Symptoms in Men (CG97)
d) Any NHS England-issued clinical guidelines related to OAB management
2. Locally Adopted Guidelines
For any of the above guidelines that your Trust follows, please provide the title, version number, and date of the current guidance or policy document in use.
3. Local Protocols or Deviations
If your Trust does not follow one or more of the national guidelines listed above, or has developed local clinical pathways or protocols for the management of OAB, please provide a copy of the relevant local policy or a summary of the key differences compared to national guidance.

Under the Freedom of Information Act 2000, I would like to request the following information:
1. For each of the last five years (or as many years as data is available), please provide:
o The total number of patients recorded on the urgent referral cancer treatment pathway.
o The number of these patients whose waiting time was stopped due to an enabling treatment, as defined in the National Cancer Waiting Times Monitoring Dataset Guidance.
2. If available without exceeding cost limits, please also provide a breakdown by:
o Type of enabling treatment used (e.g., stent, dental treatment, or any others as set out in National Cancer Waiting Times Monitoring Dataset Guidance)

I am writing to request information under the Freedom of Information Act 2000.
You are receiving this request as it is believed you operate an NHS-run SARC or provide a SARC service on behalf of the NHS.

The information being requested is contained in the attached Microsoft Word document.